Sökning: "transient gene expression"
Visar resultat 1 - 5 av 150 avhandlingar innehållade orden transient gene expression.
1. Gene and protein expression in denervated atrophic and hypertrophic skeletal muscle
Sammanfattning : Following denervation skeletal muscles change their functional and structural properties. Some changes resemble conditions in developing muscles and may be important for reinnervation. Due to inactivity following denervation most skeletal muscles loose muscle mass and become atrophic. LÄS MER
2. Global Profiling of Host Cell Gene Expression During Adenovirus Infection
Sammanfattning : To investigate mechanisms involved in virus-host interactions, global changes in host gene expression were examined during infection with adenovirus type 2 (Ad2) using cDNA microarray technology. In paper I and II, transcriptional changes in HeLa cells were investigated during the early and late phase of infection, respectively. LÄS MER
3. GH/IGF-I axis regulation of cardiovascular and neuronal gene expression and function
Sammanfattning : Abstract Cardiovascular disease is a major cause of mortality in the Western world. Another important clinical condition is brain damage due to radiation therapy in cancer patients. This has neurological impairments presenting in the survivors. For both these conditions, it is important to develop new therapeutic strategies. LÄS MER
4. Changes in gene expression during delayed neuronal death after cerebral ischemia in the rat
Sammanfattning : After transient global cerebral ischemia, selected populations of neurons in the brain will die after a period of 2-3 days, a phenomenon termed delayed neuronal death. This is of clinical importance as delayed neuronal death has been found to occur in humans as well. LÄS MER
5. Design, expression, and analysis of antibody-based blood-brain barrier shuttles
Sammanfattning : Antibody therapeutics, with their strong and highly selective target binding, are now used to treat various diseases. However, to enable their use to treat brain disorders, they must be delivered across the blood-brain barrier (BBB), as without active transport, only around 0.01% of intravenously injected doses reach the brain. LÄS MER